133 related articles for article (PubMed ID: 38286872)
21. Addenbrooke's cognitive examination III: diagnostic utility for detecting mild cognitive impairment and dementia in Parkinson's disease.
Sousa NMF; Brucki SMD
Arq Neuropsiquiatr; 2023 Feb; 81(2):155-163. PubMed ID: 36863401
[TBL] [Abstract][Full Text] [Related]
22. Predictors of cognitive impairment in an early stage Parkinson's disease cohort.
Hu MT; Szewczyk-Królikowski K; Tomlinson P; Nithi K; Rolinski M; Murray C; Talbot K; Ebmeier KP; Mackay CE; Ben-Shlomo Y
Mov Disord; 2014 Mar; 29(3):351-9. PubMed ID: 24395708
[TBL] [Abstract][Full Text] [Related]
23. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
[TBL] [Abstract][Full Text] [Related]
24. Elevated Levels of Serum Neurofilament Light Chain Associated with Cognitive Impairment in Vascular Dementia.
Ma W; Zhang J; Xu J; Feng D; Wang X; Zhang F
Dis Markers; 2020; 2020():6612871. PubMed ID: 33204362
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis of possible mild cognitive impairment in Parkinson's disease: validity of the SCOPA-Cog.
Isella V; Mapelli C; Morielli N; Siri C; De Gaspari D; Pezzoli G; Antonini A; Poletti M; Bonuccelli U; Picchi L; Napolitano A; Vista M; Appollonio IM
Parkinsonism Relat Disord; 2013 Dec; 19(12):1160-3. PubMed ID: 24011719
[TBL] [Abstract][Full Text] [Related]
26. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
[TBL] [Abstract][Full Text] [Related]
27. Serum neurofilament light chain and inflammatory cytokines as biomarkers for early detection of mild cognitive impairment.
Jing X; Wang L; Song M; Geng H; Li W; Huo Y; Huang A; Wang X; An C
Sci Rep; 2024 Apr; 14(1):9072. PubMed ID: 38643230
[TBL] [Abstract][Full Text] [Related]
28. Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.
Faust-Socher A; Duff-Canning S; Grabovsky A; Armstrong MJ; Rothberg B; Eslinger PJ; Meaney CA; Schneider RB; Tang-Wai DF; Fox SH; Zadikoff C; Kennedy N; Chou KL; Persad C; Litvan I; Mast BT; Gerstenecker AT; Weintraub S; Reginold W; Marras C
Dement Geriatr Cogn Disord; 2019; 47(4-6):187-197. PubMed ID: 31315127
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
[TBL] [Abstract][Full Text] [Related]
30. Assessing Mild Cognitive Impairment in Parkinson's Disease by Magnetic Resonance Quantitative Susceptibility Mapping Combined Voxel-Wise and Radiomic Analysis.
Zhao Y; Qu H; Wang W; Liu J; Pan Y; Li Z; Xu G; Hu C
Eur Neurol; 2022; 85(4):280-290. PubMed ID: 35313305
[TBL] [Abstract][Full Text] [Related]
31. Plasma NfL, clinical subtypes and motor progression in Parkinson's disease.
Pilotto A; Imarisio A; Conforti F; Scalvini A; Masciocchi S; Nocivelli S; Turrone R; Gipponi S; Cottini E; Borroni B; Rizzetti MC; Pizzi M; Bonanni L; Sturchio A; Espay AJ; Zetterberg H; Ashton NJ; Hye A; Padovani A
Parkinsonism Relat Disord; 2021 Jun; 87():41-47. PubMed ID: 33964785
[TBL] [Abstract][Full Text] [Related]
32. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
[TBL] [Abstract][Full Text] [Related]
33. Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology.
Gao Y; Nie K; Huang B; Mei M; Guo M; Xie S; Huang Z; Wang L; Zhao J; Zhang Y; Wang L
Neurosci Lett; 2017 Sep; 658():121-132. PubMed ID: 28823894
[TBL] [Abstract][Full Text] [Related]
34. Associations of sleep disorders with serum neurofilament light chain levels in Parkinson's disease.
Qi WY; Sun Y; Guo Y; Tan L
BMC Neurol; 2024 May; 24(1):147. PubMed ID: 38693483
[TBL] [Abstract][Full Text] [Related]
35. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
Aamodt WW; Waligorska T; Shen J; Tropea TF; Siderowf A; Weintraub D; Grossman M; Irwin D; Wolk DA; Xie SX; Trojanowski JQ; Shaw LM; Chen-Plotkin AS
Mov Disord; 2021 Dec; 36(12):2945-2950. PubMed ID: 34480363
[TBL] [Abstract][Full Text] [Related]
36. Global assessment, cognitive profile, and characteristics of mild cognitive impairment in Parkinson's disease.
Yang J; Pourzinal D; Byrne GJ; McMahon KL; Copland DA; O'Sullivan JD; Mitchell L; Dissanayaka NN
Int J Geriatr Psychiatry; 2023 Jun; 38(6):e5955. PubMed ID: 37318156
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Cognitive-Driven Performance-Based Activities of Daily Living Dysfunction in Parkinson's Disease.
Sulzer P; Bäumer A; Hoang HG; Becker S; Lönneker HD; Graessel E; Liepelt-Scarfone I
J Int Neuropsychol Soc; 2020 Apr; 26(4):430-440. PubMed ID: 31822319
[TBL] [Abstract][Full Text] [Related]
38. Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment.
Samat NA; Abdul Murad NA; Mohamad K; Abdul Razak MR; Mohamed Ibrahim N
Front Neurosci; 2017; 11():712. PubMed ID: 29326545
[No Abstract] [Full Text] [Related]
39. Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients.
Santiago JA; Potashkin JA
PLoS One; 2015; 10(11):e0142582. PubMed ID: 26566043
[TBL] [Abstract][Full Text] [Related]
40. Assessing the utility of the Movement Disorder Society Task Force Level 1 diagnostic criteria for mild cognitive impairment in Parkinson's disease.
Szeto JY; Mowszowski L; Gilat M; Walton CC; Naismith SL; Lewis SJ
Parkinsonism Relat Disord; 2015 Jan; 21(1):31-5. PubMed ID: 25465744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
